ABOT Pharmaceuticals: Major
Health Technology
Mkt Cap
94.5B
P/E (TTM)
11.37
EPS
81.37
ROE
28.59%
Div Yield
4.15%
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 75.40B | 68.18B | 55.48B | 49.26B | 42.57B | |
| Cost of Goods Sold | -50.13B | -49.29B | -44.14B | -35.38B | -27.22B | |
| Gross Profit | 25.27B | 18.89B | 11.34B | 13.88B | 15.35B | |
| SG&A Expenses | -12.34B | -10.26B | -8.76B | -7.63B | -7.00B | |
| Research & Development | -136.36M | -81.06M | -24.94M | — | — | |
| Depreciation | -1.89B | -1.77B | -1.57B | -1.42B | -1.23B | |
| Other Operating Expense | -300.03M | -278.04M | -634.97M | -161.19M | -221.32M | |
| Total Operating Expense | -62.77B | -59.82B | -53.53B | -43.17B | -34.44B | |
| Operating Income (EBIT) | 12.62B | 8.35B | 1.95B | 6.09B | 8.13B | |
| Interest Income | 546.00M | 464.36M | 739.17M | 881.80M | 571.13M | |
| Interest Expense | -75.66M | -23.61M | -30.29M | -32.30M | -61.78M | |
| Equity in Earnings | 0 | 0 | 0 | 0 | 0 | |
| Other Non-Operating Income | 126.65M | 227.44M | -1.11B | -788.64M | -225.84M | |
| Total Non-Operating Income | 875.88M | 668.18M | 96.27M | 60.86M | 283.51M | |
| Pre-Tax Income | 13.50B | 9.02B | 2.04B | 6.15B | 8.41B | |
| Income Tax | -5.53B | -3.79B | -1.78B | -3.14B | -2.44B | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |
| Net Income | 7.97B | 5.23B | 261.78M | 3.00B | 5.97B | |
| EBITDA | 14.51B | 10.13B | 3.53B | 7.53B | 9.38B | |
| EPS (Basic) | 81.37 | 53.46 | 2.67 | 30.69 | 60.95 | |
| EPS (Diluted) | 81.37 | 53.46 | 2.67 | 30.69 | 60.95 | |
| Gross Margin | 33.51% | 27.71% | 20.44% | 28.17% | 36.06% | |
| Operating Margin | 16.74% | 12.25% | 3.51% | 12.36% | 19.09% | |
| EBITDA Margin | 19.25% | 14.86% | 6.36% | 15.29% | 22.04% | |
| Pre-Tax Margin | 17.90% | 13.23% | 3.68% | 12.48% | 19.76% | |
| Net Margin | 10.57% | 7.68% | 0.47% | 6.10% | 14.02% |